This is a parallel group, single institution, prospective clinical study. The purpose of this study is to assess whether the Jawbone Up 24, a consumer based accelerometer, can be a feasible tool to study physical activity in cancer patients and patients with Amyotrophic Lateral Sclerosis (ALS).

Inclusion Criteria:

• Patients > = 18 years of age.
• Patient must be able to ambulate and complete the 6 minute walk test without use of a walker, cane, or any assist devices.
• Cancer patients or ALS patients who meet the following criteria:

Prostate cancer:

• Histologically confirmed prostate cancer.
• Patients who are initiating any chemotherarpy (examples are docetaxel, cabazitaxel, etc.) and/or hormone directed treatment for prostate cancer. Examples of hormone directed therapy include GnRH agonist or antagonists (such as leuprolide, goserelin, triptorelin, histrelin and degarelix), androgen receptor blockers (such as bicalutamide or enzalutamide), or androgen biosynthesis inhibitors (such as abiraterone).

Renal cancer:

• Histologically confirmed renal cell carcinoma (RCC).
• Metastatic disease, in the opinion of the treating provider.
• Starting any systemic therapy for metastatic disease

Brain cancer:

• Histologically confirmed high grade glioma.
• Status post concurrent radiation therapy and daily temozolomide.
• Starting adjuvant temozolomide therapy.

ALS patients who are:

• Already on a stable dose of Riluzole for at least one month.
• ALSFRS-R with \

This is a parallel group, single institution, prospective clinical study.